Drug intelligence / Profile preview

amroitinib

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules

Overview

Amroitinib is a pharmaceutical drug currently undergoing clinical investigation for the treatment of various cancers, including stage IIIA non-small cell lung cancer and high-grade soft tissue sarcomas. It is likely a small molecule, indicated by its hydrochloride salt form. The drug is being studied in combination with first-line chemotherapy for lung cancer and as a treatment for soft tissue sarcomas. Its specific mechanism of action has not been publicly disclosed in the provided clinical trial contexts or general search results.

Other names: Amroitinib hydrochloride

Beyond the preview

Go deeper on amroitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amroitinib.

Explore the full profile